Subgroup	No. of Patients	Indobufen	Aspirin	Hazard Ratio (95%CI)	p for interaction
		no. of events (%)*			
Overall	5834	213 (7·9)	175 (6·4)	1·23 (1·01-1·50)	
Sex					0·054
Male	3517	143 (8·2)	100 (5·7)	1·43 (1·11-1·85)	
Female	1921	70 (7·3)	75 (7·8)	0·93 (0·67-1·30)	
Age					0·84
<65 yr	2858	86 (6·2)	72 (4·9)	1·24 (0·91-1·70)	
>65 yr	2580	127 (9·6)	103 (8·2)	1·19 (0·91-1·54)	
Diabetes					0·32
Yes	1452	72 (9·8)	50 (7·0)	1·45 (1·00-2·09)	
No	3986	141 (7·1)	125 (6·2)	1·15 (0·90-1·46)	
Hypertension					0·49
Yes	3403	147 (8·6)	115 (6·8)	1·29 (1·01-1·64)	
No	2035	66 (6·5)	60 (5·9)	1·08 (0·76-1·55)	
Etiological stroke subtype					0·97
Large artery atherosclerosis	1453	84 (11·8)	73 (9·8)	1·21 (0·88-1·66)	
Small artery occlusion	1951	53 (5·4)	37 (3·8)	1·40 (0·91-2·14)	
Undetermined pathogenesis	1364	58 (8·7)	45 (6·5)	1·35 (0·91-2·01)	
Others	388	15 (7·5)	15 (8·0)	0·87 (0·41-1·82)	
Intracranial artery stenosis					0·47
Yes	2800	133 (9·6)	113 (8·0)	1·22 (0·95-1·58)	
No	2316	72 (6·2)	49 (4·3)	1·44 (1·00-2·08)	
Previous antiplatelet therapy					0·66
Yes	411	21 (10·0)	19 (9·5)	0·91 (0·48-1·73)	
No	5027	192 (7·7)	156 (6·2)	1·24 (1·01-1·54)	
Disease severity					0·051
NIHSS < 10	4923	194 (7·9)	148 (6·0)	1·33 (1·07-1·64)	
NIHSS ≥ 10	515	19 (7·4)	27 (10·5)	0·71 (0·38-1·33)	
Onset to Randomization time					0·31
<24 hrs	691	34 (9·2)	33 (10·2)	0·78 (0·47-1·29)	
24-48 hrs	2177	82 (7·6)	63 (5·7)	1·34 (0·96-1·87)	
48-72 hrs	2570	97 (7·6)	79 (6·1)	1·27 (0·94-1·71)